Novel anticancer therapy in BCG unresponsive non-muscle-invasive bladder cancer

References

• DeGeorge KC, Holt HR, Hodges SC. Bladder cancer: diagnosis and treatment. Am Fam Physician. 2017;96(8):507‐514.
   PubMed Web of Science ®Google Scholar
• Cumberbatch MGK, Noon AP. Epidemiology, aetiology and screening of bladder cancer. Transl Androl Urol. 2019;8(1):5‐11.
   PubMed Web of Science ®Google Scholar
• Un M, Trinh QD. Diagnosis and staging of bladder cancer. Hematol Oncol Clin North Am. 2015;29(2):205‐vii.
   Web of Science ®Google Scholar
• Cassell A, Yunusa B, Jalloh M, et al. Non-muscle invasive bladder cancer: a review of the current trend in Africa. World J Oncol. 2019;10(3):123‐131.
   Google Scholar
• Sexton WJ, Wiegand LR, Correa JJ, et al. Bladder cancer: a review of non-muscle invasive disease. Cancer Control. 2010;17(4):256‐268.
   PubMed Web of Science ®Google Scholar
• Alhunaidi O, Zlotta AR. The use of intravesical BCG in urothelial carcinoma of the bladder. Ecancermedicalscience. 2019;13:905.
   PubMed Web of Science ®Google Scholar
• Moschini M, Zamboni S, Mattei A, et al. Bacillus Calmette-Guérin unresponsiveness in non-muscle-invasive bladder cancer patients: what the urologists should know. Minerva Urol Nefrol. 2019;71(1):17‐30.
   PubMed Web of Science ®Google Scholar
• Zlotta AR, Fleshner NE, Jewett MA. The management of BCG failure in non-muscle-invasive bladder cancer: an update. Can Urol Assoc J. 2009;3(6 Suppl 4):S199–S205.
   PubMedGoogle Scholar
• Gual Frau J, Palou J, Rodríguez O, et al. Failure of Bacillus Calmette-Guérin therapy in non-muscle-invasive bladder cancer: definition and treatment options. Fracaso del tratamiento con Bacilo de Calmette-Guérin en cáncer de vejiga sin invasión muscular: definición y opciones de tratamiento. Arch Esp Urol. 2016;69(7):423–433.
   PubMedGoogle Scholar
• Werntz RP, Adamic B, Steinberg GD. Emerging therapies in the management of high-risk non-muscle invasive bladder cancer (HRNMIBC). World J Urol. 2019;37(10):2031‐2040.
   PubMed Web of Science ®Google Scholar
• Meng MV, Gschwend JE, Shore N, et al. Emerging immunotherapy options for bacillus Calmette-Guérin unresponsive nonmuscle invasive bladder cancer. J Urol. 2019;202(6):1111‐1119.
   PubMed Web of Science ®Google Scholar
• Anastasiadis A, de Reijke TM. Best practice in the treatment of nonmuscle invasive bladder cancer. Ther Adv Urol. 2012;4(1):13‐32.
   PubMedGoogle Scholar
• Taylor J, Becher E, Steinberg GD. Update on the guideline of guidelines: non-muscle-invasive bladder cancer. BJU Int. 2020;125(2):197‐205.
   Web of Science ®Google Scholar
• Soukup V, Čapoun O, Cohen D, et al. Risk stratification tools and prognostic models in non-muscle-invasive bladder cancer: a critical assessment from the European association of urology non-muscle-invasive bladder cancer guidelines panel. Eur Urol Focus. 2020;6(3):479‐489.
   PubMedGoogle Scholar
• Isharwal S, Konety B. Non-muscle invasive bladder cancer risk stratification. Indian J Urol. 2015;31(4):289‐296.
   PubMed Web of Science ®Google Scholar
• Seo KW, Kim BH, Park CH, et al. The efficacy of the EORTC scoring system and risk tables for the prediction of recurrence and progression of non-muscle-invasive bladder cancer after intravesical bacillus calmette-guerin instillation. Korean J Urol. 2010;51(3):165‐170.
   Google Scholar
• Fernandez-Gomez J, Madero R, Solsona E, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol. 2009;182(5):2195‐2203.
   PubMed Web of Science ®Google Scholar
• Cambier S, Sylvester RJ, Collette L, et al. EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1–3 years of maintenance bacillus Calmette-Guérin. Eur Urol. 2016;69(1):60‐69.
   PubMed Web of Science ®Google Scholar
• van Rhijn BW, Zuiverloon TC, Vis AN, et al. Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. Eur Urol. 2010;58(3):433‐441.
   PubMed Web of Science ®Google Scholar
• Passoni N, Gayed B, Kapur P, et al. Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer. Urol Oncol. 2016;34(11):485.e7‐485.e14.
   PubMed Web of Science ®Google Scholar
• Shiota M, Fujimoto N, Yamamoto Y, et al. Genome-wide association study of genetic variations associated with treatment failure after intravesical bacillus Calmette-Guérin therapy for non-muscle invasive bladder cancer [published online ahead of print, 2020 Mar 2]. Cancer Immunol Immunother. 2020;69:1155–1163.
   PubMed Web of Science ®Google Scholar
• Kamat AM, Li R, O’Donnell MA, et al. Predicting response to intravesical bacillus Calmette-Guérin immunotherapy: are we there yet? A systematic review. Eur Urol. 2018;73(5):738‐748.
   Web of Science ®Google Scholar
• Woldu SL, Bagrodia A, Lotan Y. Guideline of guidelines: non-muscle-invasive bladder cancer. BJU Int. 2017;119(3):371‐380.
   PubMed Web of Science ®Google Scholar
• Flaig TW, Spiess PE, Agarwal N, et al. Bladder cancer, version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(3):329‐354.
   PubMedGoogle Scholar
• Babjuk M, Burger M, Compérat EM, et al. European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma In Situ) - 2019 update. Eur Urol. 2019;76(5):639‐657.
   PubMed Web of Science ®Google Scholar
• Lerner SP, Dinney C, Kamat A, et al. Clarification of bladder cancer disease states following treatment of patients with intravesical BCG. Bladder Cancer. 2015;1(1):29‐30.
   Web of Science ®Google Scholar
• Li R, Tabayoyong WB, Guo CC, et al. Prognostic implication of the united states food and drug administration-defined BCG-unresponsive disease. Eur Urol. 2019;75(1):8‐10.
   Web of Science ®Google Scholar
• Kamat AM, Sylvester RJ, Böhle A, et al. Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the international bladder cancer group. J Clin Oncol. 2016;34(16):1935‐1944.
   PubMed Web of Science ®Google Scholar
• Kamat AM, Lerner S, Black P, et al. Once BCG unresponsive, always BCG unresponsive: an open letter to the FDA to enhance recruitment into clinical trials in bladder cancer. Bladder Cancer. 2017;3(3):145‐146.
   Web of Science ®Google Scholar
• Kamat AM, Gontero P, Palou J. How should I manage a patient with tumor recurrence despite adequate bacille Calmette-Guérin? Eur Urol Oncol. 2020;3(2):252‐257.
   Web of Science ®Google Scholar
• Giannarini G, Birkhäuser FD, Recker F, et al. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist’s failure to detect urothelial carcinoma of the upper urinary tract and urethra. Eur Urol. 2014;65(4):825‐831.
   Web of Science ®Google Scholar
• von Rundstedt FC, Lerner SP. Bacille-Calmette-Guerin non-responders: how to manage. Transl Androl Urol. 2015;4(3):244‐253.
   PubMed Web of Science ®Google Scholar
• Hassler MR, Shariat SF, Soria F. Salvage therapeutic strategies for bacillus Calmette-Guerin failure. Curr Opin Urol. 2019;29(3):239‐246.
   PubMed Web of Science ®Google Scholar
• Porten SP, Leapman MS, Greene KL. Intravesical chemotherapy in non-muscle-invasive bladder cancer. Indian J Urol. 2015;31(4):297‐303.
   PubMed Web of Science ®Google Scholar
• Williams SK, Hoenig DM, Ghavamian R, et al. Intravesical therapy for bladder cancer. Expert Opin Pharmacother. 2010;11(6):947‐958.
   Web of Science ®Google Scholar
• Skinner EC, Goldman B, Sakr WA, et al. SWOG S0353: phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guérin. J Urol. 2013;190(4):1200‐1204.
   Web of Science ®Google Scholar
• Dalbagni G, Russo P, Sheinfeld J, et al. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder. J Clin Oncol. 2002;20(15):3193‐3198.
   PubMed Web of Science ®Google Scholar
• Dalbagni G, Russo P, Bochner B, et al. Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder. J Clin Oncol. 2006;24(18):2729‐2734.
   Web of Science ®Google Scholar
• Bassi P, De Marco V, Tavolini IM, et al. Pharmacokinetic study of intravesical gemcitabine in carcinoma in situ of the bladder refractory to bacillus Calmette-Guérin therapy. Urol Int. 2005;75(4):309‐313.
   Web of Science ®Google Scholar
• Gacci M, Bartoletti R, Cai T, et al. Intravesical gemcitabine in BCG-refractory T1G3 transitional cell carcinoma of the bladder: a pilot study. Urol Int. 2006;76(2):106‐111.
   PubMed Web of Science ®Google Scholar
• Gunelli R, Bercovich E, Nanni O, et al. Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study. Br J Cancer. 2007;97(11):1499‐1504.
   PubMed Web of Science ®Google Scholar
• Mohanty NK, Nayak RL, Vasudeva P, et al. Intravesicle gemcitabine in management of BCG refractory superficial TCC of urinary bladder-our experience. Urol Oncol. 2008;26(6):616‐619.
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G, Perdonà S, Damiano R, et al. Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial. Cancer. 2010;116(8):1893‐1900.
   PubMed Web of Science ®Google Scholar
• Addeo R, Caraglia M, Bellini S, et al. Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. J Clin Oncol. 2010;28(4):543‐548.
   PubMed Web of Science ®Google Scholar
• Perdonà S, Di Lorenzo G, Cantiello F, et al. Is gemcitabine an option in BCG-refractory nonmuscle-invasive bladder cancer? A single-arm prospective trial. Anticancer Drugs. 2010;21(1):101‐106.
   PubMed Web of Science ®Google Scholar
• McKiernan JM, Masson P, Murphy AM, et al. Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. J Clin Oncol. 2006;24(19):3075‐3080.
   PubMed Web of Science ®Google Scholar
• Laudano MA, Barlow LJ, Murphy AM, et al. Long-term clinical outcomes of a phase I trial of intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to standard intravesical therapy. Urology. 2010;75(1):134‐137.
   PubMed Web of Science ®Google Scholar
• Barlow LJ, McKiernan JM, Benson MC. The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience. World J Urol. 2009;27(3):331‐335.
   PubMed Web of Science ®Google Scholar
• Bassi PF, Volpe A, D’Agostino D, et al. Paclitaxel-hyaluronic acid for intravesical therapy of bacillus Calmette-Guérin refractory carcinoma in situ of the bladder: results of a phase I study. J Urol. 2011;185(2):445‐449.
   PubMed Web of Science ®Google Scholar
• McKiernan JM, Barlow LJ, Laudano MA, et al. A phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of bacillus Calmette-Guérin refractory nonmuscle invasive bladder cancer. J Urol. 2011;186(2):448‐451.
   Web of Science ®Google Scholar
• McKiernan JM, Holder DD, Ghandour RA, et al. Phase II trial of intravesical nanoparticle albumin bound paclitaxel for the treatment of nonmuscle invasive urothelial carcinoma of the bladder after bacillus Calmette-Guérin treatment failure. J Urol. 2014;192(6):1633‐1638.
   Web of Science ®Google Scholar
• Dinney CP, Greenberg RE, Steinberg GD. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin. Urol Oncol. 2013;31(8):1635‐1642.
   Web of Science ®Google Scholar
• Luo Y, Chen X, Downs TM, et al. IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guérin immunotherapy. J Immunol. 1999;162(4):2399‐2405.
   PubMed Web of Science ®Google Scholar
• Joudi FN, Smith BJ, O’Donnell MA, et al. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol. 2006;24(4):344‐348.
   Web of Science ®Google Scholar
• Nepple KG, Lightfoot AJ, Rosevear HM, et al. Bladder cancer genitourinary oncology study group. Bacillus Calmette-Guérin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer. J Urol. 2010;184(5):1915‐1919.
   Web of Science ®Google Scholar
• Rosevear HM, Lightfoot AJ, Birusingh KK, et al. Factors affecting response to bacillus Calmette-Guérin plus interferon for urothelial carcinoma in situ. J Urol. 2011;186(3):817‐823.
   PubMed Web of Science ®Google Scholar
• Hadaschik BA, Ter Borg MG, Jackson J, et al. Paclitaxel and cisplatin as intravesical agents against non-muscle-invasive bladder cancer. BJU Int. 2008;101(11):1347‐1355.
   Web of Science ®Google Scholar
• Chen CH, Yang HJ, Shun CT, et al. A cocktail regimen of intravesical mitomycin-C, doxorubicin, and cisplatin (MDP) for non-muscle-invasive bladder cancer. Urol Oncol. 2012;30(4):421‐427.
   Web of Science ®Google Scholar
• Breyer BN, Whitson JM, Carroll PR, et al. Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer. Urol Oncol. 2010;28(5):510‐514.
   PubMed Web of Science ®Google Scholar
• Huang D, Jin YH, Weng H, et al. Combination of intravesical Bacille Calmette-Guérin and chemotherapy vs. bacille Calmette-Guérin alone in non-muscle invasive bladder cancer: a meta-analysis. Front Oncol. 2019;9:121.
   PubMed Web of Science ®Google Scholar
• Tan WS, Kelly JD. Intravesical device-assisted therapies for non-muscle-invasive bladder cancer. Nat Rev Urol. 2018;15(11):667‐685.
   PubMed Web of Science ®Google Scholar
• Liu K, Zhu J, Song YX, et al. Thermal intravesical chemotherapy reduce recurrence rate for non-muscle invasive bladder cancer patients: a meta-analysis. Front Oncol. 2020;10:29.
   PubMed Web of Science ®Google Scholar
• Liem EI, Crezee H, de la Rosette JJ, et al. Chemohyperthermia in non-muscle-invasive bladder cancer: an overview of the literature and recommendations. Int J Hyperthermia. 2016;32:363–373.
   PubMed Web of Science ®Google Scholar
• Tan WS, Panchal A, Buckley L, et al. Radiofrequency-induced thermo-chemotherapy effect versus a second course of bacillus Calmette-Guérin or institutional standard in patients with recurrence of non-muscle-invasive bladder cancer following induction or maintenance bacillus Calmette-Guérin Therapy (HYMN): a phase III, open-label, randomised controlled trial. Eur Urol. 2019;75(1):63‐71.
   Web of Science ®Google Scholar
• Alfred Witjes J, Hendricksen K, Gofrit O, et al. Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party. World J Urol. 2009;27(3):319‐324.
   Web of Science ®Google Scholar
• Lammers RJ, Witjes JA, Inman BA, et al. The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review. Eur Urol. 2011;60(1):81‐93.
   Web of Science ®Google Scholar
• Volpe A, Racioppi M, Bongiovanni L, et al. Thermochemotherapy for non-muscle-invasive bladder cancer: is there a chance to avoid early cystectomy? Urol Int. 2012;89(3):311‐318.
   PubMed Web of Science ®Google Scholar
• de Jong JJ, Hendricksen K, Rosier M, et al. Hyperthermic intravesical chemotherapy for BCG unresponsive non-muscle invasive bladder cancer patients. Bladder Cancer. 2018;4(4):395‐401.
   Web of Science ®Google Scholar
• Racioppi M, Di Gianfrancesco L, Ragonese M, et al. ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk “BCG failure” non muscle invasive bladder cancer: 3 years follow-up outcomes. BMC Cancer. 2018;18(1):1224.
   PubMedGoogle Scholar
• Di Stasi SM, Giannantoni A, Stephen RL, et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol. 2003;170(3):777‐782.
   Web of Science ®Google Scholar
• Manyak MJ, Ogan K. Photodynamic therapy for refractory superficial bladder cancer: long-term clinical outcomes of single treatment using intravesical diffusion medium. J Endourol. 2003;17(8):633‐639.
   PubMed Web of Science ®Google Scholar
• Bader MJ, Stepp H, Beyer W, et al. Photodynamic therapy of bladder cancer - a phase I study using hexaminolevulinate (HAL). Urol Oncol. 2013;31(7):1178‐1183.
   PubMed Web of Science ®Google Scholar
• Waidelich R, Stepp H, Baumgartner R, et al. Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer. J Urol. 2001;165(6 Pt 1):1904‐1907.
   PubMed Web of Science ®Google Scholar
• Farina MS, Lundgren KT, Bellmunt J. Immunotherapy in urothelial cancer: recent results and future perspectives. Drugs. 2017;77(10):1077‐1089.
   PubMed Web of Science ®Google Scholar
• Hurwitz AA, Watkins SK. Immune suppression in the tumor microenvironment: a role for dendritic cell-mediated tolerization of T cells. Cancer Immunol Immunother. 2012;61(2):289‐293.
   PubMed Web of Science ®Google Scholar
• Fu C, Jiang A. Dendritic cells and CD8 T cell immunity in tumor microenvironment. Front Immunol. 2018;9:3059.
   PubMed Web of Science ®Google Scholar
• Chen Y, Song Y, Du W, et al. Tumor-associated macrophages: an accomplice in solid tumor progression. J Biomed Sci. 2019;26(1):78.
   PubMed Web of Science ®Google Scholar
• Chi LJ, Lu HT, Li GL, et al. Involvement of T helper type 17 and regulatory T cell activity in tumour immunology of bladder carcinoma. Clin Exp Immunol. 2010;161(3):480‐489.
   PubMed Web of Science ®Google Scholar
• Knochelmann HM, Dwyer CJ, Bailey SR, et al. When worlds collide: th17 and Treg cells in cancer and autoimmunity. Cell Mol Immunol. 2018;15(5):458–469.
   PubMed Web of Science ®Google Scholar
• Mukherjee N, Ji N, Hurez V, et al. Intratumoral CD56bright natural killer cells are associated with improved survival in bladder cancer. Oncotarget. Published 2018 Nov 23;9(92):36492‐36502.
   Google Scholar
• Zhou J, Tang Z, Gao S, et al. Tumor-associated macrophages: recent insights and therapies. Front Oncol. 2020;10:188.
   PubMed Web of Science ®Google Scholar
• Bohner P, Chevalier MF, Cesson V, et al. Double positive CD4+CD8+ T cells are enriched in urological cancers and favor T helper-2 polarization. Front Immunol. 2019;10:622.
   PubMed Web of Science ®Google Scholar
• Joseph M, Enting D. Immune responses in bladder cancer-role of immune cell populations, prognostic factors and therapeutic implications. Front Oncol. 2019;9:1270.
   PubMed Web of Science ®Google Scholar
• Crispen PL, Kusmartsev S. Mechanisms of immune evasion in bladder cancer. Cancer Immunol Immunother. 2020;69(1):3‐14.
   PubMed Web of Science ®Google Scholar
• Barclay J, Creswell J, León J. Cancer immunotherapy and the PD-1/PD-L1 checkpoint pathway. Inmunoterapia contra el cáncer y la ruta del punto de control PD-1/PD-L1. Arch Esp Urol. 2018;71(4):393‐399.
   PubMed Web of Science ®Google Scholar
• Francisco LM, Sage PT, Sharpe AH, et al. pathway in tolerance and autoimmunity. Immunol Rev. 2010;236:219‐242.
   PubMed Web of Science ®Google Scholar
• Thibult ML, Mamessier E, Gertner-Dardenne J, et al. PD-1 is a novel regulator of human B-cell activation. Int Immunol. 2013;25(2):129‐137.
   PubMed Web of Science ®Google Scholar
• Nakanishi J, Wada Y, Matsumoto K, et al. Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother. 2007;56(8):1173‐1182.
   PubMed Web of Science ®Google Scholar
• Fukumoto K, Kikuchi E, Mikami S, et al. Clinical role of programmed cell death-1 expression in patients with non-muscle-invasive bladder cancer recurring after initial bacillus Calmette-Guérin therapy. Ann Surg Oncol. 2018;25(8):2484‐2491.
   Web of Science ®Google Scholar
• Inman BA, Sebo TJ, Frigola X, et al. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer. 2007;109(8):1499‐1505.
   PubMed Web of Science ®Google Scholar
• Biot C, Rentsch CA, Gsponer JR, et al. Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer. Sci Transl Med. 2012;4(137):137ra72.
   PubMed Web of Science ®Google Scholar
• Pichler R, Fritz J, Zavadil C, et al. Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical bacillus Calmette-Guérin therapy in bladder cancer. Oncotarget. 2016;7(26):39916‐39930.
   Google Scholar
• Miyake M, Tatsumi Y, Gotoh D, et al. Regulatory T cells and tumor-associated macrophages in the tumor microenvironment in non-muscle invasive bladder cancer treated with intravesical bacille Calmette-Guérin: a long-term follow-up study of a Japanese cohort. Int J Mol Sci. 2017;18(10):2186.
   PubMed Web of Science ®Google Scholar
• Stenehjem DD, Tran D, Nkrumah MA, et al. PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer. Onco Targets Ther. Published 2018 Sep 19;11:5973‐5989.
   PubMed Web of Science ®Google Scholar
• Balar AV, Kulkarni GS, Uchio EM, et al. Keynote 057: phase II trial of pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guerin (BCG). J Clin Oncol. 2019;37:350.
   PubMed Web of Science ®Google Scholar
• Merck Sharp & Dohme Corp. Efficacy and safety of pembrolizumab (MK-3475) in combination with bacillus Calmette-Guerin (BCG) in high-risk non-muscle invasive bladder cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676). NLM identifier: NCT03711032. [ cited 2020 May 28]. Available from: https://clinicaltrials.gov/ct2/show/NCT03711032
   Google Scholar
• University of Oxford. Pembrolizumab in intermediate risk recurrent non-muscle invasive bladder cancer (NMIBC) (PemBla). NLM identifier: NCT03167151. [ cited 2020 May 28]. Available from: https://clinicaltrials.gov/ct2/show/NCT03167151
   Google Scholar
• National Cancer Institute (NCI). Atezolizumab in treating patients with recurrent BCG-unresponsive non-muscle invasive bladder cancer. NLM identifier: NCT02844816. [ cited 2020 May 28]. Available from: https://clinicaltrials.gov/ct2/show/NCT02844816
   Google Scholar
• Roche H-L. Safety and pharmacology study of atezolizumab alone and in combination with bacille Calmette-Guérin (BCG) in high-risk non-muscle-invasive bladder cancer (NMIBC) participants. NLM identifier: NCT02792192. [ cited 2020 May 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT02792192
   Google Scholar
• Lee Moffitt H Cancer center and research institute. Phase 2 durvalumab (Medi4736) for bacillus calmette-guérin (BCG) refractory urothelial carcinoma in situ of the bladder. NLM identifier: NCT02901548. [ cited 2020 May 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT02901548
   Google Scholar
• Hellenic GenitoUrinary Cancer Group. Efficacy of durvalumab in non-muscle-invasive bladder cancer. NLM identifier: NCT03759496. [ cited 2020 May 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT03759496
   Google Scholar
• Noah Hahn MD. ADAPT-BLADDER: modern immunotherapy in BCG-relapsing urothelial carcinoma of the bladder. NLM identifier: NCT03317158. [ cited 2020 May 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT03317158
   Google Scholar
• Squibb B-M. A study of nivolumab or nivolumab plus experimental medication BMS-986205 with or without bacillus calumette-guerin (BCG) in BCG unresponsive bladder cancer that has not invaded into the muscle wall of the bladder (CheckMate 9UT). NLM identifier: NCT03519256. [ cited 2020 May 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT03519256
   Google Scholar
• University of Oklahoma. Avelumab plus bacille calmette-guerin (BCG) in patients with non-muscle invasive bladder cancer. NLM identifier: NCT03892642. [ cited 2020 May 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT03892642
   Google Scholar
• Institut Paoli-Calmettes. Bladder PREserVation by radiotherapy and immunotherapy in BCG unresponsive non-muscle invasive bladder cancer (PREVERT). NLM identifier: NCT03950362. [ cited 2020 May 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT03950362
   Google Scholar
• Yentz S, Smith D. Indoleamine 2,3-dioxygenase (IDO) inhibition as a strategy to augment cancer immunotherapy. BioDrugs. 2018;32(4):311‐317.
   PubMed Web of Science ®Google Scholar
• Prendergast GC, Malachowski WP, DuHadaway JB, et al. Discovery of IDO1 inhibitors: from bench to bedside. Cancer Res. 2017;77(24):6795‐6811.
   Web of Science ®Google Scholar
• Prendergast GC, Malachowski WJ, Mondal A, et al. Indoleamine 2,3-dioxygenase and its therapeutic inhibition in cancer. Int Rev Cell Mol Biol. 2018;336:175‐203.
   PubMed Web of Science ®Google Scholar
• Moon YW, Hajjar J, Hwu P, et al. Targeting the indoleamine 2,3-dioxygenase pathway in cancer. J Immunother Cancer. 2015;3:51.
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhang J, Zhang Z, et al. Overexpression of indoleamine 2,3-dioxygenase 1 promotes epithelial-mesenchymal transition by activation of the IL-6/STAT3/PD-L1 pathway in bladder cancer. Transl Oncol. 2019;12(3):485‐492.
   Web of Science ®Google Scholar
• Hornyák L, Dobos N, Koncz G, et al. The role of indoleamine-2,3-dioxygenase in cancer development, diagnostics, and therapy. Front Immunol. 2018;9:151.
   PubMed Web of Science ®Google Scholar
• Mitchell TC, Hamid O, Smith DC, et al. Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, open-label phase I/II trial (ECHO-202/KEYNOTE-037). J Clin Oncol. 2018;36(32):3223‐3230.
   Web of Science ®Google Scholar
• Fishman MN, Thompson JA, Pennock GK, et al. Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies. Clin Cancer Res. 2011;17(24):7765‐7775.
   Web of Science ®Google Scholar
• Wen J, Zhu X, Liu B, et al. Targeting activity of a TCR/IL-2 fusion protein against established tumors. Cancer Immunol Immunother. 2008;57(12):1781‐1794.
   PubMed Web of Science ®Google Scholar
• Altor BioScience. A study of ALT-801 in patients with bacillus calmette-guerin (BCG) failure non-muscle invasive bladder cancer. NLM identifier: NCT01625260. [ cited 2020 May 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01625260
   Google Scholar
• Kim PS, Kwilas AR, Xu W, et al. IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas. Oncotarget. 2016;7(13):16130‐16145.
   Google Scholar
• Gomes-Giacoia E, Miyake M, Goodison S, et al. Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion. PLoS One. 2014;9(6):e96705.
   PubMed Web of Science ®Google Scholar
• Altor BioScience. QUILT-3.032: A multicenter clinical trial of intravesical bacillus calmette-guerin (BCG) in combination with ALT-803 in patients with BCG unresponsive high grade non-muscle invasive bladder cancer. NLM identifier: NCT03022825. [ cited 2020 May 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT03022825
   Google Scholar
• Lee J, Soon-Shiong P, Chamie K, et al. Early phase 2 clinical results of IL-15RaFc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients demonstrating 86% CR of carcinoma in situ (CIS) (abstract P712). J Immunother Cancer Suppl. 2018;6:117.
   Google Scholar
• Madan RA, Arlen PM, Gulley JLPAN-VAC-VF. poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma. Expert Opin Biol Ther. 2007;7(4):543‐554.
   PubMed Web of Science ®Google Scholar
• Gulley JL, Arlen PM, Tsang KY, et al. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res. 2008;14(10):3060‐3069.
   Web of Science ®Google Scholar
• Weintraub MD, Li QQ, Agarwal PK. Advances in intravesical therapy for the treatment of non-muscle invasive bladder cancer (Review). Mol Clin Oncol. 2014;2(5):656‐660.
   PubMedGoogle Scholar
• Cardillo MR, Castagna G, Memeo L, et al. Epidermal growth factor receptor, MUC-1 and MUC-2 in bladder cancer. J Exp Clin Cancer Res. 2000;19(2):225‐233.
   Web of Science ®Google Scholar
• National Cancer Institute (NCI). Study of bacillus calmette-guerin (BCG) combined with PANVAC versus BCG alone in adults with high grade non-muscle invasive bladder cancer who failed at least 1 course of BCG. NLM identifier: NCT02015104. [ cited 2020 May 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT02015104
   Google Scholar
• Howells A, Marelli G, Lemoine NR, et al. Oncolytic viruses-interaction of virus and tumor cells in the battle to eliminate cancer. Front Oncol. 2017;7:195.
   PubMed Web of Science ®Google Scholar
• Chiocca EA, Rabkin SD. Oncolytic viruses and their application to cancer immunotherapy [published correction appears in cancer immunol res. 2014 Jul;2(7):699]. Cancer Immunol Res. 2014;2(4):295‐300.
   PubMed Web of Science ®Google Scholar
• Benedict WF, Tao Z, Kim CS, et al. Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein. Mol Ther. 2004;10(3):525‐532.
   PubMed Web of Science ®Google Scholar
• Dinney CP, Fisher MB, Navai N, et al. Phase I trial of intravesical recombinant adenovirus mediated interferon-α2b formulated in Syn3 for bacillus calmette-guérin failures in nonmuscle invasive bladder cancer. J Urol. 2013;190(3):850‐856.
   Web of Science ®Google Scholar
• Navai N, Benedict WF, Zhang G, et al. Phase 1b trial to evaluate tissue response to a second dose of intravesical recombinant adenoviral interferon α2b formulated in Syn3 for failures of bacillus calmette-guerin (BCG) therapy in nonmuscle invasive bladder cancer. Ann Surg Oncol. 2016;23(12):4110‐4114.
   PubMed Web of Science ®Google Scholar
• Shore ND, Boorjian SA, Canter DJ, et al. Intravesical rAd-IFNα/Syn3 for patients with high-grade, bacillus calmette-guerin-refractory or relapsed non-muscle-invasive bladder cancer: a phase ii randomized study [published correction appears in J Clin Oncol. 2019 Aug 20;37(24):2187]. J Clin Oncol. 2017;35(30):3410–3416.
   PubMed Web of Science ®Google Scholar
• FKD Therapies Oy. INSTILADRIN® in patients with bacillus calmette-guerin (BCG) unresponsive non-muscle invasive bladder cancer (NMIBC). NLM identifier: NCT02773849. [ cited 2020 May 31]. Available from: https://clinicaltrials.gov/ct2/show/NCT02773849
   Google Scholar
• Potts KG, Hitt MM, Moore RB. Oncolytic viruses in the treatment of bladder cancer. Adv Urol. 2012;2012:404581.
   PubMedGoogle Scholar
• Ramesh N, Ge Y, Ennist DL, et al. CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor–armed oncolytic adenovirus for the treatment of bladder cancer. Clin Cancer Res. 2006;12(1):305‐313.
   PubMed Web of Science ®Google Scholar
• Burke JM, Lamm DL, Meng MV, et al. A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. J Urol. 2012;188(6):2391‐2397.
   PubMed Web of Science ®Google Scholar
• Packiam VT, Lamm DL, Barocas DA, et al. An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: interim results. Urol Oncol. 2018;36(10):440‐447.
   Web of Science ®Google Scholar
• Sverrisson EF, Espiritu PN, Spiess PE. New therapeutic targets in the management of urothelial carcinoma of the bladder. Res Rep Urol. 2013;5:53‐65.
   PubMedGoogle Scholar
• Kowalski M, Entwistle J, Cizeau J, et al. A phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCGrefractory and BCG-intolerant patients. Drug Des Devel Ther. 2010;4:313‐320.
   PubMed Web of Science ®Google Scholar
• Kowalski M, Guindon J, Brazas L, et al. A phase II study of oportuzumab monatox: an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette-Guérin. J Urol. 2012;188(5):1712‐1718.
   PubMed Web of Science ®Google Scholar
• Viventia Bio. Vicinium treatment for subjects with non-muscle invasive bladder cancer previously treated with BCG. NLM identifier: NCT03258593. [ cited 2020 June 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT02449239
   Google Scholar
• National Cancer Institute (NCI). Durvalumab and vicinium in subjects with high-grade non-muscle-invasive bladder cancer previously treated with bacillus calmette-guerin (BCG). NLM identifier: NCT03258593. [ cited 2020 June 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT03258593
   Google Scholar
• Tian T, Li X, Zhang J. mTOR signaling in cancer and mTOR inhibitors in solid tumor targeting therapy. Int J Mol Sci. 2019;20(3):755.
   PubMed Web of Science ®Google Scholar
• Douglass L, Schoenberg M. The future of intravesical drug delivery for non-muscle invasive bladder cancer. Bladder Cancer. 2016;2(3):285‐292.
   PubMed Web of Science ®Google Scholar
• Aadi LLC Phase 1/2 study of ABI-009 in nonmuscle invasive bladder cancer. NLM identifier: NCT02009332. [ cited 2020 June 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT02009332
   Google Scholar
• Dalbagni G, Benfante N, Sjoberg DD, et al. Single arm phase I/II study of everolimus and intravesical gemcitabine in patients with primary or secondary carcinoma In Situ of the bladder who failed bacillus calmette guerin (NCT01259063). Bladder Cancer. 2017;3(2):113‐119.
   PubMed Web of Science ®Google Scholar
• Junker K, van Oers JM, Zwarthoff EC, et al. Fibroblast growth factor receptor 3 mutations in bladder tumors correlate with low frequency of chromosome alterations. Neoplasia. 2008;10(1):1‐7.
   PubMed Web of Science ®Google Scholar
• Hahn NM, Bivalacqua TJ, Ross AE, et al. A phase II trial of dovitinib in BCG-unresponsive urothelial carcinoma with FGFR3 mutations or overexpression: hoosier cancer research network trial HCRN 12-157. Clin Cancer Res. 2017;23(12):3003‐3011.
   Web of Science ®Google Scholar
• Noguera-Ortega E, Secanella-Fandos S, Eraña H, et al. Nonpathogenic mycobacterium brumae inhibits bladder cancer growth in vitro, ex vivo, and in vivo. Eur Urol Focus. 2016;2(1):67–76.
   PubMedGoogle Scholar
• Noguera-Ortega E, Rabanal RM, Gómez-Mora E, et al. Intravesical mycobacterium brumae triggers both local and systemic immunotherapeutic responses against bladder cancer in mice. Sci Rep. 2018;8(1):15102.
   PubMedGoogle Scholar
• Noguera-Ortega E, Blanco-Cabra N, Rabanal RM, et al. Mycobacteria emulsified in olive oil-in-water trigger a robust immune response in bladder cancer treatment. Sci Rep. 2016;6:27232.
   PubMed Web of Science ®Google Scholar
• Morales A, Herr H, Steinberg G, et al. Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression after failed treatment with bacillus Calmette-Guérin. J Urol. 2015;193(4):1135–1143.
   PubMed Web of Science ®Google Scholar
• Li R, Amrhein J, Cohen Z, et al. Efficacy of mycobacterium phlei cell wall-nucleic acid complex (MCNA) in BCG-unresponsive patients. Bladder Cancer. 2017;3(1):65–71.
   PubMed Web of Science ®Google Scholar
• Domingos-Pereira S, Hojeij R, Reggi E, et al. Local Salmonella immunostimulation recruits vaccine-specific CD8 T cells and increases regression of bladder tumor. Oncoimmunology. 2015;4(7):e1016697.
   PubMed Web of Science ®Google Scholar
• Domingos-Pereira S, Cesson V, Chevalier MF, et al. Preclinical efficacy and safety of the Ty21a vaccine strain for intravesical immunotherapy of non-muscle-invasive bladder cancer. Oncoimmunology. 2016;6(1):e1265720.
   PubMed Web of Science ®Google Scholar